Drug survival of metformin in patients with hidradenitis suppurativa

Despite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.

Automated summary

Despite limited scientific evidence, this retrospective cohort study conducted in Spain found that metformin has a relatively long drug survival in people with hidradenitis suppurativa. Half of the patients were still using metformin after one year of treatment, and one in five patients continued the treatment after two years.